A Study to Learn More About Using Different Markers to Assess Kidney Function in Patients Before and After Methotrexate Therapy

Overview

About this study

The purpose of this study is to investigate the role that cystatin C and other novel renal biomarkers can have on improving the dosing and monitoring of adults hospitalized for treatment with high-dose methotrexate.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • ≥18 years of age and planned HD-MTX within 7-days of enrollment. 

Exclusion Criteria:

  • Those with AKI (KDIGO stage 1 or higher44) 
  • Pregnancy 
  • Those on renal replacement therapy at the time of enrollment 
  • Prisoners

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Jason Barreto, Pharm.D., R.Ph.

Open for enrollment

Contact information:

Holly Nelson

(507)293-6140

Nelson.Holly1@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20387444

Mayo Clinic Footer